Brexanolone(Lipocine Inc)

布瑞诺龙

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameBrexanolone(Lipocine Inc)
Drug Alias NameOral Brexanolone(Lipocine Inc)别孕烷醇酮Allopregnanolone(Lipocine Inc)口服布瑞诺龙Oral allopregnanolone(Lipocine Inc) +[8] 
ClassificationSmall molecules
Mechanisms of ActionGamma-aminobutyric acid A receptor positive allosteric modulators
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLipocine Inc
China Registration ClassN/A

Develop Information

Active CompaniesLipocine Inc
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, Major
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A